Business
InvestmentPitch Media Video Discusses Newly Listed Rakovina Therapeutics, a Developer of New Cancer Treatments Targeting Critical DNA Damage Response Mutations - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2021) -  Rakovina Therapeutics In...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"InvestmentPitch Media Video Discusses Newly Listed Rakovina Therapeutics, a Developer of New Cancer Treatments Targeting Critical DNA Damage Response Mutations - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - April 5, 2021) -  Rakovina Therapeutics Inc. is one of the latest new listings on the TSX Venture Exchange, trading under the symbol \"RKV\", following its qualifying transaction with Capital Pool Company Vincero Capital. The company's focus is the development of new cancer treatments and is researching and developing new precision medicines targeting critical DNA damage response mutations that are the hallmarks of many cancers.For more information, please view the InvestmentPitch Media \"video\" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Rakovina\" in the search box.Cannot view this video? Visit:https://www.youtube.com/watch?v=SGZqbMf4U6cThe company has acquired certain rights to three classes of novel preclinical small-molecule drug candidates with well established proof-of-concept. The company's initial research activities focus primarily around the kt-2000 series of PARP inhibitors, a type of targeted cancer drug. PARP is a key enzyme involved in sensing and repairing DNA single-strand breaks, which if left unrepaired, will devolve into double-strand breaks, which are lethal to the cancer cell.PARP-inhibitors prevent PARP from repairing single strand breaks, leading to increased double strand breaks. Cancer cells that are deficient in double strand break repair, such as those with BRCA mutations, will be killed indirectly by blocking PARP in a process known as \"synthetic lethality\".Damage response mutations can be considered the Achilles' heel of many tumors including breast, ovarian, prostate and pancreatic cancer. These mutations allow tumor cells to evade the human immune system and grow into life-threatening cancer, but they also define potential cancer-specific vulnerabilities that can be targeted with new precision medicine approaches. Management believes that damage response mutations will provide opportunities to personalize therapy to specific biological features of a patient's tumor, thereby leading to high-value treatments with fewer side effects and improved t...